Science World Report | Biogen Faces Delay in FDA Action Date Zacks.com Biogen is also looking to expand Tysabri's label and is conducting a phase IIIb study (ASCEND) in combination with daclizumab in patients with secondary-progressive MS - results are expected in 2015. The delay in Plegridy's approval date should not be ... Biogen Idec Inc (NASDAQ:BIIB): A Biotech Pioneer With A Stellar Future |
